The U.S. Food and Drug Administration (FDA) declined to approve Spero Therapeutics Inc.’s oral antibiotic drug for the treatment of patients with complicated urinary tract infections, the company said on Monday.
https://www.pharmalive.com/wp-content/uploads/2022/06/ReutersFDA6-10-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-06-27 16:27:022022-06-28 10:52:57U.S. FDA declines to approve Spero’s urinary tract infection drug
